Prevention of Alzheimer disease: Encouraging evidence

Canadian Family Physician

Volumn 52, Issue FEB., 2006, Pages 200-207

  Scalco, Monica Zavaloni ^a   van Reekum, Robert ^b  

^a Whitby Mental Health Centre   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CHOLESTEROL; ESTROGEN; GESTAGEN; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SELEGILINE; SIMVASTATIN;

ALZHEIMER DISEASE; BLOOD PRESSURE REGULATION; CASE CONTROL STUDY; CLINICAL OBSERVATION; CLINICAL TRIAL; DIET THERAPY; EVIDENCE BASED MEDICINE; FAMILY MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; LONGITUDINAL STUDY; MENOPAUSE; META ANALYSIS; PATIENT EDUCATION; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRIMARY PREVENTION; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ARTICLE; COGNITIVE FUNCTION TEST; DIET; EDUCATION; GENETIC SCREENING; GINKGO BILOBA; HEALTHY LIFESTYLE; NEUROIMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); GENERAL PRACTICE; HEALTH PROMOTION; RISK FACTOR;

ALZHEIMER DISEASE; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; HEALTH PROMOTION; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 33645320012     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Thal JT, Carta A, Doody R, Leber P, Mohs R, Schneider L, et al. Prevention of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(3):46-9.
2. Pope SK, Shue VM, Beck C. Will a healthy lifestyle help prevent Alzheimer's disease? Ann Rev Public Health 2003;24:111-32.
3. Forster DP, Newens AJ, Kay DW, Edwardson JA. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in northern England. J Epidemiol Community Health 1995;49(3):253-8.
4. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol 1998;55:964-8.
5. Temple V, Jozsvai E, Konstantareas MM, Hewitt TA. Alzheimer dementia in Down's syndrome: the relevance of cognitive ability. J Intellect Disabil Res 2001;45:47-55.
6. Oliver C, Crayton L, Holland A, Hall S, Bradbury J. A four-year prospective study of age-related cognitive change in adults with Down's syndrome. Psychol Med 1998;28(6):1365-77.
7. De Ronchi D, Fratiglioni L, Rucci P, Paternico A, Graziani S, Dalmonte E. The effect of education on dementia occurrence in an Italian population with middle to high socioeconomic status. Neurology 1998;50:1231-8.
8. Baldi I, Lebailly P, Mohamed-Brahim B, Letenneur L, Dartigues JF, Brochard P. Neurodegenerative diseases and exposure to pesticides in the elderly. Am J Epidemiol 2003;157(5):409-14.
9. Fleminger S, Oliver DL, Lovestone S, Rabe-Hesketh S, Giora A. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on, a partial replication. J Neurol Neurosurg Psychiatry 2003;74:857-62.
10. Ganguli M, Burmeister LA, Seaberg EC, Belle S, DeKosky ST. Association between dementia and elevated TSH: a community-based study. Biol Psychiatry 1996;40:714-25.
11. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam Study. Clin Endocrinol (Oxf) 2000;53(6):733-7.
12. Wu C, Zhou D, Wen C, Zhang L, Como P, Qiao Y. Relationship between blood pressure and Alzheimer's disease in Linxian County, China. Life Sci 2003;72(10):1125-33.
13. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen Project. A 6-year follow-up study. Arch Neurol 2003;60:223-8.
14. van Exel E, de Craen AJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, Macfarlane PW, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002;51:716-21.
15. Sheehan B, Fazel S. Elevated plasma total homocysteine levels increased the risk for dementia in the elderly. ACP J Club 2002;137(2):76.
16. Xu WL, Qiu CX, Wahlin A, Winblad B, Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004;63:1181-6.
17. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61:661-6.
18. Honig LS, Tang MX, Albert S, Costa R, Luchsinger J, Manly J, et al. Stroke and the risk of Alzheimer disease [published erratum appears in Arch Neurol 2003;61:368]. Arch Neurol 2003;60:1707-12.
19. Aarsland D, Andersen K, Larsen JP, Lolk A, Krag-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease an 8-year prospective study. Arch Neurol 2003;60:387-92.
20. Wilson RS, Schneider JA, Bienias JL, Evans DA, Bennett DA. Parkinsonianlike signs and risk of incident Alzheimer disease in older persons. Arch Neurol 2003;60:539-44.
21. Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with "reversible dementia": a controlled study. Am J Psychiatry 1993;150:1693-9.
22. Devanand DP, Sano M, Tang M, Taylor S, Gurland BJ, Wilder D, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996;53:175-82.
23. Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner CS. A twin study of late-onset depression and apolipoprotein E e4 as risk factors for Alzheimer's disease. Biol Psychiatry 1997;41:851-6.
24. Jorm AF, Van Duijn CM, Chandra V, Fratiglioni L, Graves AB, Heyman A, et al. Psychiatric history and related exposures as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20(Suppl 2):S43-7.
25. Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004;75:1662-6.
26. Bruscoli M, Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatrics 2004;16(2):129-40.
27. Welsh AK, Butters N, Hughes J, Mohs R, Heyman A. Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991;48:278-81.
28. Welsh AK, Butters N, Hughes JP, Mohs RC, Heyman A. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the consortium to estabilish a registry for Alzheimer's disease. Arch Neurol 1992;49:448-52.
29. Visser PJ, Verhey FR, Ponds RW, Cruts M, Van Broeckhoven CL, Jolles J. Course of objective memory impairment in non-demented subjects attending a memory clinic and predictors of outcome. Int J Geriatr Psychiatry 2000;15:363-72.
30. Bischkopf J, Busse A, Angermeyer MC. Mild cognitive impairment - a review of prevalence, incidence and outcome according to current approaches. Acta Psychiatr Scand 2002;106:403-14.
31. Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003;179:52-76.
32. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003;226(2):315-36.
33. Chetelat G, Baron JC. Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003;18(2):525-41.
34. De Santi S, De Leon MJ, Rusinek H, Convit A, Tarshish CY, Roche A. et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529-39.
35. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-13.
36. El Fakhri G, Kijewski MF, Jonhson KA, Syrkin G, Killiany RJ, Becker JA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol 2003;60:1066-72.
37. Van der Cammen TJ, Croes EA, Dermaut B, De Jager M, Cruts M, Van Broeckhoven C, et al. Genetic testing has no place as a routine diagnostic test in sporadic and familial cases of Alzheimer's disease. J Am Geriatr Soc 2004;52:2110-3.
38. Rocchi A, Pellegrini S, Siciliano G. Murri L. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull 2003;61(1):1-24.
39. Laws SM, Hone E, Gandy S, Martins RN. Expanding the association between the APOE gene and the risk of Alzheimer's disease: possible roles for APOE promoter polymorphisms and alterations in APOE transcription. J Neurochem 2003;84(6):1215-36.
40. Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS. et al. Preservation of cognitive function with antihypertensive medications. A longitudinal analysis of a community-based sample of African Americans. Arch Intern Med 2002;162:2090-6.
41. Forette F, Seux M, Staessen JA, Thijs L, Babarskiene M, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study [published erratum in Arch Intern Med 2003;163:241]. Arch Intern Med 2002;162:2046-52.
42. Forette F, Seux M, Staessen JA, Lutgarde T, Birkenhager WH, Babarskiene M, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
43. Michikawa M. Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease? J Neurosci Res 2003;72(2):141-6.
44. Burns M, Duff K. Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. Neurochem Res 2003;28(7):979-86.
45. Simons M, Schwarzler F, Lutjohann D, Bergman K, Beyreuther K, Dichgans J, et al. Treatment with simvastin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002;52:346-50.
46. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003;60:194-200.
47. Solfrizzi V, Panza F, Capurso A. The role of diet in cognitive decline. J Neurotransmission 2003;110(1):95-110.
48. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol 2004;3:579-87.
49. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer's disease. Arch Neurol 2002;59:1258-63.
50. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues J, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002;325:932-3.
51. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Wilson RS, et al. Consumption of fish and 3-n fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-6.
52. Hu FB, Willet WC. Optimal diets for prevention of coronary heart disease. JAMA 2002;288:2569-78.
53. Hooper L, Thompson R, Harrison R, Summerbell C, Moore H, Worthington H, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;CD003177.
54. Engelhart MJ, Geerlings MI, Ruitenberg A, Swieten JC, Hofman A, Witteman JC, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002;287:3223-9.
55. Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 2002;287:3230-7.
56. Luchsinger JA, Tang M, Shea S, Mayeux R. Antioxidant vitamin intake and risk of Alzheimer disease. Arch Neurol 2003;60:203-8.
57. Letenneur L. Risk of dementia and alcohol and wine consumption: a review of recent results. Biol Res 2004;37(2):189-93.
58. Friedland RP. Fish consumption and the risk of Alzheimer disease. Is it time to make dietary recommendations? Arch Neurol 2003;60:923-4.
59. Wilson RS, Bennett DA, Bienias JL, Aggarwal NT, Mendes De Leon CF, Morris MC, et al. Cognitive activity and incident AD in a population-based sample of older persons. Neurology 2002;59:1910-4.
60. Wilson RS, Mendes de Leon CE, Barnes LL, Schneider JA, Bienias JL, Evans DA, et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002;287:742-8.
61. Lytle ME, Bilt JV, Pandav RS, Dodge HH, Ganguli M. Exercise level and cognitive decline. Alzheimer Dis Assoc Disord 2004;18:57-64.
62. Heyn P, Abreu BC, Ottenbacker KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004;85:1694-704.
63. Laurin D, Verreault R, Lindsay J, MacPherson K, Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch Neurol 2001;58:498-504.
64. Weuve J, Kang JH, Manson JE, Breteler MMB, Ware JH, Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA 2004;292:1454-61.
65. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al. Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study. Neurology 1995;45:1161-8.
66. Schuit AJ, Feskens EJM. Launer LJ, Kromhout D. Physical activity and cognitive decline, the role of the apolipoprotein e4 allele. Med Sci Sports Exerc 2001;33(5):772-7.
67. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive functions in post-menopausal women: a meta-analysis. Neuroscienre 2000;101(3):485-512.
68. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugates equine estrogen and the incidence of probable dementia and mild cognitive impairment in post-menopausal women. JAMA 2004;291:2947-58.
69. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA 2002;288:2123-9.
70. Fillit HM. The role of hormone replacement therapy in the prevention of Alzheimer disease. Arch Intern Med 2002;162:1934-42.
71. Etminan M, Gill S, Samil A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 2003;327:128-31.
72. Launer L. Nonsteroidal anti-inflammatory drug use and the risk for Alzheimer's disease: dissecting the epidemiological evidence. Drugs 2003;63(8):731-9.
73. Sano M, Ernesto C,Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
74. Tabet N, Birks J, Evans JG, Orrel M, Spector A. Vitamin E for Alzheimer's disease. Cochrane Database Syst Rev 2000;4:CD002854.
75. Bjelakovic G, Nikolova D, Simonetti RG, Gludd C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004;364:1219-28.
76. Berman K, Brodaty H. Tocopherol (vitamin E) in Alzheimer's disease and other neurodegenerative disorders. CNS Drugs 2004:18(12):807-25.
77. Delagarza V. Pharmacologic treatment of Alzheimer's disease: an update. Am Fam Physician 2003;68(7):1365-72.
78. Birks J, Grimley EV, Van Dorgen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002;4:CD003120.